Zinzino reported its preliminary sales results for November 2025. Zinzino group revenue grew 45% overall year-over-year. Zinzino sales markets grew 49% year-over-year, reaching $39 million, while Faun Pharma’s external sales experienced decline.
Accumulated revenue from January 2025 to November 2025 increased by 54% year-over-year to $320 million.
The Asia-Pacific market, which includes Australia, New Zealand, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand, China, Philippines and South Korea, saw the strongest revenue momentum, growing 309% year-over-year. North America, which includes Canada, US and Mexico, was also a momentum driver, posting 174% growth year-over-year. Majority of its other markets, including the Nordics, Central Europe, South and West Europe, the Baltics and Africa also showed significant revenue growth year-over-year.
